Genomics & Epigenomics
The main objective of this scientific programme is to use large-scale analyses of clinical samples (canceromics) to identify candidate biomarkers in cancer. The analyses involve genomic sequencing, studies of DNA methylation, and genome and transcriptome microarrays.
The profile of cancer cell gene expression and modifications can give specific information about stage of illness, prognosis and treatment response for a given patient. Scientists in this programme identify biomarkers with the potential of revealing cancer in the patient. This information will in the future guide early diagnosis and tailored cancer treatment.
Central activities in this programme
- Determination of early and late events in tumourigenesis
- Subclassification of tumour staging with prognostic/therapeutic impact
- Assessment of tumour heterogeneity
- Identification of markers of metastatic processes
- Identification of prognostic impact of genome changes
- Identification of novel fusion oncogenes
- Identification of novel master keys in cancer